Search results
Showing 1 to 15 of 40 results for eczema
This guideline covers diagnosing and managing atopic eczema in children under 12. It aims to improve care for children with atopic eczema by making detailed recommendations on treatment and specialist referral. The guideline also explains how healthcare professionals should assess the effect eczema has on quality of life, in addition to its physical severity.
This guideline sets out an antimicrobial prescribing strategy for secondary bacterial infection of eczema and covers infection of other common skin conditions. It aims to optimise antibiotic use and reduce antibiotic resistance. The recommendations are for adults, young people and children aged 72 hours and over. They do not cover diagnosis.
This quality standard covers diagnosing and managing atopic eczema in children under 12. It describes high-quality care in priority areas for improvement.
View quality statements for QS44Show all sections
Sections for QS44
- Quality statements
- Quality statement 1: Assessment at diagnosis
- Quality statement 2: Stepped approach to management
- Quality statement 3: Psychological wellbeing and quality of life
- Quality statement 4: Provision of emollients
- Quality statement 5: Referral for specialist dermatological advice
- Quality statement 6: Specialist allergy investigation
- Quality statement 7: Treatment of eczema herpeticum
All NICE products on eczema. Includes any guidance and quality standards.
Evidence-based recommendations on tacrolimus (Protopic) and pimecrolimus (Elidel) for people with atopic eczema.
Alitretinoin for the treatment of severe chronic hand eczema (TA177)
Evidence-based recommendations on alitretinoin (Toctino) for treating severe chronic hand eczema in adults.
Frequency of application of topical corticosteroids for atopic eczema (TA81)
Evidence-based recommendations on using topical corticosteroids for people with atopic eczema.
This guideline covers assessing and managing food allergy in children and young people under 19. It aims to improve symptoms such as faltering growth and eczema by offering advice on how to identify food allergy and when to refer to secondary or specialist care.
This guideline covers diagnosing and managing varicose veins in people aged 18 and over. It aims to ensure that people understand the options for treating varicose veins and that healthcare professionals know when to refer people for specialist assessment and treatment.
This quality standard covers diagnosing, assessing and managing food allergy in children and young people (under 19) and adults. It describes high-quality care in priority areas for improvement.
View quality statements for QS118Show all sections
Sections for QS118
- Quality statements
- Quality statement 1: Allergy-focused clinical history
- Quality statement 2: Diagnosing IgE-mediated food allergy
- Quality statement 3: Diagnosing non-IgE-mediated food allergy
- Quality statement 4: Referral to secondary or specialist care
- Quality statement 5 (placeholder): Diagnosing food allergy in adults
- Quality statement 6 (placeholder): Nutritional support for food allergy
- Update information
Lebrikizumab for treating moderate to severe atopic dermatitis in people 12 years and over [ID4025]
In development [GID-TA11349] Expected publication date: TBC
This quality standard covers diagnosing and managing varicose veins in the legs of adults (aged 18 and over). It includes referral for specialist assessment and treatment options. It describes high-quality care in priority areas for improvement.
Delgocitinib for treating moderate to severe chronic hand eczema ID6408
Awaiting development [GID-TA11506] Expected publication date: TBC
Dupilumab for treating moderate to severe atopic dermatitis (TA534)
Evidence-based recommendations on dupilumab (Dupixent) for treating moderate to severe atopic dermatitis in adults.
Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis (TA814)
Evidence-based recommendations on abrocitinib (Cibinqo), tralokinumab (Adtralza) or upadacitinib (Rinvoq) for treating moderate to severe atopic dermatitis.